Startup | April 28, 2026
Orange Health records Rs 138 crore revenue at 65% annual growth in FY26
The company achieved 20% EBITDA profitability in Bengaluru and reached operational profitability across all its active cities
The company achieved 20% EBITDA profitability in Bengaluru and reached operational profitability across all its active cities
Deploys $40 million in Hyderabad; advances APIs, peptides, and global small molecule capabilities
Experts call for integrated, evidence-based approaches to tackle rising dengue, malaria, and chikungunya burden in Indian cities
The submission is backed by positive results from the Phase 3 AFFIRM study
The lens received U.S. Food and Drug Administration (FDA) market authorization via the De Novo pathway in late 2025
His appointment is expected to strengthen scientific input in policy discussions across public health, biotech, and translational research
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Gilenya Capsules, 0.5 mg of Novartis Pharmaceuticals Corporation (Novartis)
The first Phase III and second Phase III trials will be multi-centre, randomised, assessor-blind, active-comparator studies to determine the efficacy, safety and tolerability of orally administered Zintrodiazine
New appointments bring diagnostics and medtech expertise to strengthen healthcare delivery and policy engagement
Over the past decade, IIL has maintained a strong growth trajectory, registering a compound annual growth rate (CAGR) of 16%
Subscribe To Our Newsletter & Stay Updated
